For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211125:nRSY5901Ta&default-theme=true
RNS Number : 5901T Allergy Therapeutics PLC 25 November 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Vesting and Granting of Awards under Long Term Incentive Plan
Allergy Therapeutics (AIM: AGY), the fully integrated pharmaceutical company
specialising in allergy vaccines, announces that:
Vesting of Award
Performance conditions attaching to provisional awards ("Awards") made
pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three
years ended 1 November 2021, details of which were announced on 1 November
2018, have been met in part.
Consequently, on 22 November 2021, Allergy Therapeutics granted certain of its
director's options ("Options") over the Company's Ordinary Shares of 0.1 pence
in replacement for the Awards made under the LTIP as follows:
Director Percentage of Award Vested Total number of Ordinary Shares over which Options granted Exercise Price
Manuel Llobet 89.3% 803,700 0.1 pence
Nick Wykeman 89.3% 401,850 0.1 pence
In accordance with the rules of the LTIP, 50% of these Options are exercisable
immediately and the remaining 50% are subject to a holding period of three
years. The exercise period is ten years from date of grant.
Granting of Award
Pursuant to the Company's Long Term Incentive Plan ("LTIP") the following
conditional awards of Ordinary Shares of 0.1 pence each were made to Executive
Directors at a nominal cost of 0.1 pence each on 22 November 2021 ("New
Awards").
Executive Director Number of Conditional shares awarded (New Awards)
Manuel Llobet 900,000
Nick Wykeman 450,000
The New Awards have been granted in accordance with the LTIP rules and vesting
is conditional on the satisfaction of performance conditions in respect of
earnings growth and share price growth over three years.
Following the above share transactions, the Executive Directors hold the
following:
Director Unvested LTIP Awards Options Interest in Ordinary Shares
Manuel Llobet 2,700,000 1,676,200 3,325,000
Nick Wykeman 1,350,000 838,100 300,000
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Manuel Llobet
2 Reason for the notification
a) Position/status Chief Executive Office and PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ALLERGY THERAPEUTICS PLC
b) LEI LEIR97215202003301009534776
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Conditional award of shares and grant of share options under the Company's
Long Term Incentive Plan
b) Identification code GB00B02LCQ05
c) Nature of the transaction Grant of conditional Awards
d) Price(s) and volume(s) Awards Price(s) Volume(s)
Options 0.1 pence 803,700
New Awards 0.1 pence 900,000
e) Aggregated information
1,703,700
0.1 pence
f) Date of the transaction 22 November 2021
g) Place of the transaction Outside a trading venue
e)
Aggregated information
1,703,700
0.1 pence
f)
Date of the transaction
22 November 2021
g)
Place of the transaction
Outside a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Nick Wykeman
2 Reason for the notification
a) Position/status Chief Financial Officer and PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ALLERGY THERAPEUTICS PLC
b) LEI LEIR97215202003301009534776
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Conditional award of shares and grant of share options under the Company's
Long Term Incentive Plan
b) Identification code GB00B02LCQ05
c) Nature of the transaction Grant of conditional awards
d) Price(s) and volume(s) Awards Price(s) Volume(s)
Options 0.1 pence 401,850
New Awards 0.1 pence 450,000
e) Aggregated information
851,850
0.1 pence
f) Date of the transaction 22 November 2021
g) Place of the transaction Outside a trading venue
e)
Aggregated information
851,850
0.1 pence
f)
Date of the transaction
22 November 2021
g)
Place of the transaction
Outside a trading venue
This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com (mailto:christina@sternir.com)
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group
focussed on the treatment and diagnosis of allergic disorders, including
immunotherapy vaccines, that have the potential to cure disease. The Group
sells proprietary and third party products from its subsidiaries in nine major
European countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development include
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which
has achieved double digit compound annual growth since formation, employs
c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBABLTMTBTMIB